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 Abstract 
Aim Skeletal myoblasts are used in repair of ischemic myocardium. However, a large fraction 
of  grafted  myoblasts  degenerate  upon  engraftment.  Colony-stimulating  factor-1  (CSF-1) 
accelerates  myoblast  proliferation  and  angiogenesis.  We  hypothesized  that  CSF-1 
overexpression improves myoblast survival and cardiac function in ischemia-induced heart 
failure. 
Methods  and  results  Three  weeks  following  myocardial  infarction,  rats  developed  heart 
failure and received intramyocardial injections of mouse CSF-1-transfected or untransfected 
primary  autologous  rat  myoblasts,  recombinant  human  CSF-1,  mouse  CSF-1  expressing 
plasmids,  or  culture  medium.  Tissue  gene  and  protein  expression  was  measured  by 
quantitative RT-PCR and Western blotting. Fluorescence imaging and immunocytochemistry 
were used to analyze myoblasts, endothelial cells, macrophages, and infarct wall thickening. 
Electrocardiograms were recorded online using a telemetry system. Left ventricular function 
was assessed by echocardiography over time, and improved significantly only in the CSF-1-
overexpressing myoblast group. CSF-1-overexpression enhanced myoblast numbers and was 
associated  with  an  increased  infarct  wall  thickness,  enhanced  angiogenesis,  increased 
macrophage  recruitment  and  upregulated  matrix  metalloproteases  (MMP)-2  and  -12  in  the 
zone  bordering  the  infarction.  Transplantation  of  CSF-1-overexpressing  myoblasts  did  not 
result in major arrhythmias. 
Conclusion Autologous intramyocardial transplantation of CSF-1 overexpressing myoblasts 
might be a novel strategy in the treatment of ischemia-induced heart failure. 
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  1. Introduction 
For  end-stage  heart  failure  patients,  cardiac  transplantation  is  the  only  accepted  treatment 
being  offered  and  then  only  to  a  small  percentage  of  patients.  Therefore,  approaches  that 
bypass heterologous organ transplantation are highly desired. Myoblast  transplantation has 
recently received considerable attention as a means of replacing lost cardiomyocytes. Skeletal 
myoblasts possess clinically attractive characteristics, including ease of procurement, growth 
potential  in  vitro,  and  strong  resistance  to  ischemia 
1.  The  ability  of  engrafted  skeletal 
myoblasts to improve post-infarction cardiac function and to withstand long-term cardiac-type 
workload has been shown in both animal and human studies 
1-9.  
Although efficacy data resulting from early results of phase-I clinical trials involving small 
patient  cohorts  are  encouraging,  the  large  multicenter  MAGIC  trial,  which  featured  a 
randomized,  double-blind,  placebo-controlled  dose-ranging  design  will  assess  the  effect  of 
myoblast transplantation on heart function and will also provide comprehensive safety data 
and thus allow a more objective assessment of the risk-benefit ratio. 
10 A major concern in 
myoblast transplantation, besides the caveat of arrhythmic events, is the loss of a significant 
fraction of grafted myoblasts upon engraftment. In a long-term follow-up study in heart failure 
patients treated with myoblast transplantation, more than 50% of grafted segments exhibiting 
systolic thickening recovery in the short-term was reduced to 33% at long-term. This was 
consistent  with  a  high  rate  of  cell  death,  which  was  incompletely  compensated  for  by 
proliferation  within  the  scar 
11.  Consequently,  the  efficacy  of  myoblast  transplantation  is 
hampered by these facts and the clinical use of cell therapy based upon skeletal myoblasts is 
still far from being a successful therapeutic measure. 
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 Thus,  this  study  focused  on  myoblast  manipulations  that  enhance  graft  survival  and 
proliferation  on  the  one  hand  and  increase  blood  vessels  in  the  fibrous  tissue  within  the 
infarcted myocardium on the other 
10. We hypothesized that myoblasts genetically engineered 
to overexpress CSF-1 prior to transfer to the failing heart following myocardial infarction 
would improve graft survival and cardiac function. The rationale for this hypothesis is two-
fold: First, CSF-1 accelerates angiogenesis 
12,
 and affects macrophage-induced production of 
matrix metalloproteases (MMPs) that leads to extracellular matrix (ECM) remodeling 
13, 14. 
Second, proliferation of L6α1 rat myoblasts is regulated in an autocrine fashion by CSF-1 and 
this regulation is lost as they differentiate to myotubes 
15.  
 
2. Methods 
2.1 Experimental design and animals 
A total number of 270 male Sprague Dawley rats (Harlan, Borchen, Germany) were coded for 
experiments. Due to hemodynamic compromise, ventricular fibrillation, myocardial rupture 
and  bleeding  following  myocardial  infarction,  the  number  of  surviving  animals  with 
comparable base-line cardiac function was 170. These animals were randomly divided into 
groups of n=20 and treated with intramyocardial injection of: mouse CSF-1-overexpressing 
autologous rat myoblasts (MB-CSF-1), DiIC18-labeled CSF-1-overexpressing autologous rat 
myoblasts (DiI MB-CSF-1), autologous rat myoblasts (MB), DiIC18-labeled autologous rat 
myoblasts (DiI-MB), recombinant human CSF-1 (recCSF-1), mouse pCIneo-CSF-1 plasmid 
(pl-CSF-1), or culture medium (control). Sham operated rats (n= 20) were additional controls.  
Rats  were  anesthetized 
14,  intubated  tracheally  and  ventilated  with  an  oxygen/isoflurane 
mixture before undergoing a left lateral thoracotomy. The branch of the left coronary artery 
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 (LCA) was either ligated with a 7-0 polypropylene snare (Ethicon, Somerville, NJ) or left 
intact  in  sham  procedure.  At  day  (d)  7,  left  ventricular  (LV)  function  was  assessed  by 
echocardiography.  At  d21,  re-thoracotomy  was  performed,  and  150  µl  DMEM  culture 
medium, 150 µl DMEM containing 5x10
6 MB, DiI MB, MB-CSF-1, DiI MB-CSF-1, 150 µl 
Ringer's  solution  containing  10
6  IU  recCSF-1  or  10  µg  pl-CSF-1  and  Effectene  (Qiagen, 
Hilden, Germany) were injected into the infarcted myocardium using a 30-gauge needle 
16. 
The volume delivered was evenly divided between the central (two injections) and bordering 
(five  injections)  areas  of  infarcted  myocardium.  On  d52  and  d86,  the  LV  function  was 
assessed, and animals were sacrificed on day 88. For measuring CSF-1 expression levels in 
vivo, additional animals (n=6) of the control, MB, recCSF-1, pl-CSF-1, and MB-CSF-1 groups 
were sacrificed on d52. The investigation conforms to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 
85-23, revised 1996). 
 
2.2 Myoblast culture and characterization 
The right anterior tibial muscle was isolated, minced in phosphate buffered saline (PBS), and 
passed through a 100 µm sieve (BD, Franklin Lakes, NJ). Cells were cultured in DMEM 
containing 10% fetal calf serum, 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen, 
Carlsbad, CA). Cultured cells were screened using myocyte specific anti-desmin (Neomarkers, 
Fremont,  CA)  and  fibroblast  specific  antibody  (Harlan/Sera-Lab,  Sussex,  England).  The 
proportion of myoblasts was calculated (SIS image analysis, Münster, Germany) by dividing 
the number of desmin positive cells corrected to the total number of cells and ranged from 
60% to 75%. 
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2.3 Myoblast Proliferation Assay 
Myoblasts  cell
  proliferation  was  determined  using  WST-1  Reagent  (Roche  Diagnostics, 
Indianapolis,
 IN). 
 
2.4 Echocardiography and electrocardiography (ECG) 
In  anesthetized  rats,  maximal  LV  long-axis  lengths (L)  and  endocardial  area  tracing  were 
measured using a 15 MHz linear array scan head to calculate LV end-diastolic (LVEDV) and 
end-systolic  (LVESV)  volume  and  ejection  fraction  (LVEF  =  LVEDV-LVESV/LVEDV). 
Measurements utilized three consecutive cardiac cycles. A telemetry device (DataSciences, 
Arden Hills, MN) recorded ECG signals continuously 
17. 
 
2.5 Heart-to-body weight ratio, histology, immunocytochemistry 
Heart-to-body  weight  ratios  were  estimated 
18.  Heart  tissue  was  partly  formalin  fixed, 
embedded  in  paraffin,  or  prepared  for  cryo-sectioning  for  performing  histology  and 
immunocytochemistry.  
 
2.6 Fluorescence optical imaging 
In  experiments  employing  DiIC18-labeled  myoblasts,  three-dimensional  cellular  integration 
was  assessed  on  an  imaging  station  (IS2000MM,  Kodak,  Eastman  Kodak  Company,  New 
Haven, CT). The ventricles were then dissected, mechanically dissociated in collagenase and 
the DiIC18-labeled myoblasts detected on an inverted fluorescent microscope. Images were 
obtained and analyzed using morphometry software (Lucia G, Optoteam, Vienna, Austria). 
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 The percentage of DiIC18-labeled myoblasts was determined for DiIC18-labeled MB and MB-
CSF-1 groups.  
 
2.7 Quantitative Real-Time RT-PCR and Western blotting 
Real-time RT-PCR and Western blotting were performed as described 
14, 19.  
 
2.8 Statistical analysis 
The Wilcoxon rank test and analysis of variance with Bonferroni’s t-test were used to compare 
the data between the groups. Statistical tests were performed using SPSS software (version 
10.0.7,  SPSS,  Chicago,  IL).  Data  are  expressed  as  means  ±SD.  P  values  of  <  0.05  were 
considered to indicate statistical significance. 
 
Supplementary Materials and Methods are available on-line.  
 
3. Results 
3.1 CSF-1-transfected myoblasts improved myocardial function 
Baseline d7 LVEF was not different between controls (27.6%), MB (29.5%), recCSF-1 (29%), 
pl-CSF-1 (27.7%) or MB-CSF-1 (28%), although it was significantly lower vs. the sham group 
(68%). LVEF in all treated animals on d52 did not differ significantly from LVEF on d7, 
although the average LVEF in the MB-CSF-1 group was the only one increased. LVEF on d86 
was  significantly  lower  in  all  treatment  groups  vs.  sham;  however,  LVEF  for  MB-CSF-1 
group  (49%)  was  significantly  increased  vs.  d7  and  vs.  d52.  Importantly,  LVEF  was 
significantly elevated in MB-CSF-1 as compared to MB group on d52 and d86 (Figure 1A).  
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 The LVEDV was significantly elevated in controls, MB, recCSF-1, and pl-CSF-1 vs. sham. In 
contrast, LVEDV improved significantly in the MB-CSF-1 group on d86, although LVEDV 
on d7 and d52 was still significantly higher in MB-CSF-1 vs. sham. Of note, the LVEDV was 
significantly improved in MB-CSF-1 as compared to MB group on d52 and d86 (Figure 1B). 
ECG recordings
 showed that ventricular tachycardia (VT) or fibrillation (VF) were absent in 
the sham group. Within 24 hours following infarction, however, the animals developed at least 
one episode of VT or VF that terminated spontaneously. Short episodes of VT or VF were 
observed in 5 and 2  animals of the MB and  MB-CSF-1 groups, respectively; whereas no 
ventricular arrhythmias were observed in other treatment groups. The arrhythmia episodes in 
MB and MB-CSF-1 groups occurred within 7 days after myoblast engraftment, were self-
limited, and hemodynamically well tolerated. These data indicated that CSF-1-overexpressing 
myoblasts  significantly  improved  LVEF  and  attenuated  LV  dilation  associated  with  heart 
failure. 
 
3.2 CSF-1-transfected myoblasts attenuate myocardial remodeling 
Despite  similar  initial  reductions  in  LVEF  by  1  week  in  the  non-sham  groups,  the  mean 
proportion of scar tissue/normal LV myocardium on d88 post myocardial infarction was 34%, 
32%, 36% and 33% in control, MB, recCSF-1 and pl-CSF-1 groups, respectively, and tended 
to be less in rats receiving MB-CSF-1 (29%) (Figure 2A, B). The thickness of the LV infarct 
wall was increased significantly in the MB-CSF-1 (1.76 ± 0.41 mm) group, but not in the MB 
(1.35 ± 0.4 mm), recCSF-1 (1.1 ± 0.29 mm) or pl-CSF-1 (1.29 ± 0.3 mm) groups as compared 
to the controls (1.04 ± 0.23 mm). In addition, the LV wall thickness increased significantly in 
the MB-CSF-1 compared to the MB group (Figure 2C). All groups had a significantly reduced 
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 wall thickness vs. sham (2.68 ± 0.22 mm). Heart-to-body weight ratio increased significantly 
in controls, in MB, in recCSF-1, and in pl-CSF-1 groups, but not in rats receiving MB-CSF-1 
as compared to sham (Figure 2D). These results further indicated that by 12 weeks, CSF-1-
overexpressing myoblasts attenuated myocardial remodeling and reduced ventricular dilation. 
 
3.3 CSF-1 enhances myoblast survival and angiogenesis 
To  track  the  grafted  myoblasts  in  the  heart,  unmodified  (DiI-MB)  and  CSF-1-transfected 
myoblasts (DiI MB-CSF-1) were labeled with DiIC18. Cardiac function of the DiI-labeled MB 
group  was  comparable  to  the  unlabeled  MB  group  (data  not  shown).  We  employed  both 
fluorescence optical imaging of the hearts and fluorescence microscopy to analyze changes in 
myoblast number on d88 post-myocardial infarction. Visual comparison of the DiIC18 images 
revealed marked differences in the size of the area containing myoblasts between DiI-MB and 
DiI  MB-CSF-1  groups.  Treatment  with  DiI  MB-CSF-1  clearly  increased  the  area  of 
fluorescent myoblasts being found in both the infarction and the zone bordering the infarction 
region compared to DiI-MB treated animals (Figure 3A). DiIC18–labeled myoblasts in both 
MB and MB-CSF-1 groups had not formed an organized tissue within the myocardium as 
shown by fluorescence microscopy, visualization of the nuclei by DAPI staining, and HE-
staining in heart tissue sections of the same rats used for optical imaging (Figure 3B). The 
grafted myoblasts in MB and MB-CSF-1 treated animals were found in between the cardiac 
myofibers and expressed skeletal muscle myosin heavy chain (Figure 3C). No fibrotic reaction 
was seen surrounding these areas of grafted and integrated cells (Figures 3B,C). The number 
of surviving myoblasts was significantly higher in the DiI MB-CSF-1 group as compared to 
the DiI-MB group (Figure 3D). To understand whether CSF-1 gene transfer affects myoblast 
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 proliferation, we first compared unmodified and CSF-1-transfected myoblasts in an in vitro 
proliferation experiment. At 72 h post-transfection, the CSF-1-transfected myoblasts had a 
significantly  higher  proliferation  rate  than  control  untreated  myoblasts  (Figure  3E).  The 
proliferation enhancing effect of CSF-1 on myoblasts in vitro, however, was not detectable in 
vivo on d88, assessed by PCNA staining in both DiI MB and DiI MB-CSF-1 groups (Figures 
3F). 
In both the MB and MB-CSF-1 groups a large number of vessels was found in areas with 
transplanted  myoblasts  (Figures  4A-D).  Consistent  with  these  observations,  the  density  of 
vWF-positive vessels and CD-31 protein expression were significantly higher in the border 
zone  of  the  MB  and  MB-CSF-1  groups,  while  vascular  density  and  CD-31  levels  in  the 
recCSF-1 group and vascular density in the pl-CSF-1 group were unchanged as compared to 
controls (Figures 4E,F). Importantly, the density of vWF-positive vessels in MB-CSF-1 group 
was significantly higher compared to the MB group (Figure 4E). In the myocardial infarction 
zone, the average vascular density and CD-31 expression levels in the MB, pl-CSF-1, and 
MB-CSF-1 groups were not significantly different from those in control and recCSF-1 groups 
(Figures  4E,F).  These  findings  indicated  that  CSF-1  overexpression  enhances  long-term 
survival of myoblasts associated with increased angiogenesis. 
 
3.4 CSF-1 increases macrophage recruitment 
The transfection efficiency in cultured myoblasts determined in preliminary experiments with 
a green fluorescent protein reporter plasmid on d2 after transfection was approximately 70% 
declining to 45% and 20% on d7 and d14, respectively (data not shown). CSF-1 mRNA was 
overexpressed  significantly  on  d2,  d7,  and  d14  following  transfection  as  compared  to 
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 untransfected control myoblasts, respectively (Figure 5A).  In vivo gene expression analyses 
indicated that CSF-1 gene expression was still significantly increased on d52 post-myocardial 
infarction  in  the  MB-CSF-1  group  compared  to  others.  On  d88,  however,  no  significant 
changes were detectable for CSF-1 mRNA levels (Figure 5B).  
After  MB-CSF-1  treatment,  the  number  of  macrophages  in  the  border  zone  increased 
significantly on d88 post myocardial infarction compared to the control group (Figures 5C-G). 
In contrast, neither treatment with recCSF-1, pl-CSF-1 nor with MB resulted in significant 
changes  in  the  number  of  macrophages.  These  experiments  indicated  that  the  transfected 
myoblasts  retain  the  ability  to  overexpress  CSF-1  for  at  least  2  weeks  and  that  CSF-1 
expressing myoblasts are able to attract macrophages. 
 
3.5 CSF-1 affects myocardial MMP expression 
MMP-2 protein levels on d67 post-treatment were significantly increased in the border zone of 
the MB-CSF-1 compared to the control group (Figure 6A). No significant changes compared 
with controls were found in the MB, recCSF-1, and pl-CSF-1 groups in the border zone. In 
contrast, in the myocardial infarction zone, no significant changes were observed between the 
groups.  MMP-9  protein  expression  remained  unchanged  in  the  border  zone,  but  was 
significantly reduced in the myocardial infarction zone for the MB-CSF-1 and MB groups vs. 
controls. MMP-1 protein expression was not significantly altered for these groups in both 
border and myocardial infarction zones, while MMP-13 levels, similar to MMP-9, were found 
to be significantly reduced within the myocardial infarction zone in the MB-CSF-1 as well as 
the MB group vs. control. Macrophage-specific MMP-12 protein expression was significantly 
increased in the border zone of the MB-CSF-1 group compared to controls, but was not altered 
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 in  the  myocardial  infarction  zone.  In  contrast  to  these  changes  in  MMP  levels,  protein 
expression of tissue inhibitors of metalloproteinases (TIMPs) 1-4 did not significantly change 
in  the  border  or  myocardial  infarction  zone  of  any  group  (data  not  shown).  In  line  with 
Western  blot  analyses,  immunocytochemistry  revealed  significantly  higher  density  of  both 
MMP-2-  and  MMP-12-positive  cells  in  the  border  zone  of  MB-CSF-1  treated  animals 
compared to the MB group (Figure 6B). These data indicated that a specific expression pattern 
of MMPs is displayed in the myocardial border zone of CSF-1-transfected myoblasts. 
 
4. Discussion 
This study was designed to enhance the survival of grafted myoblasts and to improve the 
angiogenesis following myoblast transfer to the failing heart. It is evident that myosin heavy 
chain is not expressed in myoblasts early after engraftment; however, with time, cells fuse into 
myotubes, differentiate into myofibers, and express myosin heavy chain 
4. Therefore, those 
areas that stained positively for myosin heavy chain within the grafts reflect myoblasts that 
have survived and gone on to fuse and form myofibers. This process took place in both the 
MB  and  MB-CSF-1  groups.  However,  the  percentage  of  myoblasts  that  survived  was 
significantly  higher  in  the  MB-CSF-1  group.  Myoblast  transfer  7  days  after  myocardial 
infarction was reported to improve cardiac function 
16. However, the same procedure failed in 
our setting of ischemic heart failure, involving myoblast transfer at 21 days after myocardial 
infarction. In contrast, we found that myoblasts overexpressing CSF-1 did improve the cardiac 
function, indicating the benefit of CSF-1-transfected myoblasts in the treatment of ischemic 
heart failure. Collectively, these results might be explained by the timing of therapy initiation. 
At  three  weeks  following  infarction,  the  scar  tissue  is  more  matured  than  at  one  week, 
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 rendering rescue by myoblasts more difficult. CSF-1 expression, besides increasing long-term 
survival, might enable the grafted cells to more efficiently recruit macrophages and endothelial 
cells,  thereby  facilitating  angiogenesis  for  their  further  survival.  In  concert  with  this 
hypothesis, CSF-1 mRNA was overexpressed in the MB-CSF-1 group on d52, associated with 
increased  LVEF,  which  further  improved  on  d88.  The  higher  density  of  myoblasts  and 
macrophages and the higher vascular density in the MB-CSF-1 group in vivo, further support 
the positive role of CSF-1.  
Previous  studies  utilizing  rat  L6α1  myoblasts  showed  that  CSF-1  regulates  myoblast 
proliferation in an autocrine fashion, but that expression of both CSF-1 and the CSF-1R is lost 
upon differentiation of the myoblasts to myotubes. Indeed, the induced expression of CSF-1R 
antisense  RNA  in  these  cells  blocked  myoblast  proliferation  and  accelerated  myogenic 
differentiation 
15. Whether the proliferative effect of CSF-1 on myoblasts observed in vitro had 
contributed to the results observed in our in vivo studies, however, remains uncertain.  
The  mechanism  for  autocrine  regulation  of  myoblast  proliferation  in  vitro  by  CSF-1  is 
apparently intracellular 
15, thus we would not expect an effect of concomitant recombinant 
CSF-1 administration and myoblast transplantation on myoblast numbers. Importantly, CSF-1 
plasmid application was not as efficient as CSF-1 overexpressing cells to maintain CSF-1 gene 
expression  levels.  Myoblasts  can  be  transfected  much  more  efficiently  in  vitro  prior  to 
transplant  as  compared  to  the  protocol  utilizing  in  vivo  systemic  plasmid  administration, 
resulting in higher CSF-1 expression levels in grafted cells, which explains the failure of pl-
CSF-1 in improving angiogenesis and macrophage recruitment. 
Local production of CSF-1 has been shown to recruit and sustain many tissue macrophage 
populations which possess trophic and scavenger functions that are important for normal tissue 
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 development 
20-22. In addition, macrophages can act as supportive cells for myoblasts through 
delivery of both soluble mitogenic factors and cell contact-mediated survival signals 
23. These 
functions of the macrophages are also quite relevant to the changes observed during recovery 
from myocardial infarction (see below). Thus, another reason for the effectiveness of the MB-
CSF-1 group is that ectopic expression of CSF-1 in myoblasts increases the initial recruitment 
and survival of macrophages. 
Relevant to the important role played by macrophages in the repair of injured muscle, recent 
studies indicate that macrophages recruited from the blood to sites of muscle injury exhibit a 
non-proliferating,  pro-inflammatory  expression  profile,  but  once  within  muscle  switch  to 
become  proliferating,  anti-inflammatory  macrophages.  In  vitro,  in  contrast  to  the  pro-
inflammatory  macrophages,  which  stimulate  myoblast  proliferation,  the  anti-inflammatory 
macrophages  stimulate  myoblast  differentiation 
24.  Furthermore,  these  same  authors 
demonstrate that depletion of circulating monocytes in CD11b-diptheria toxin receptor mice at 
the time of injury totally prevented muscle regeneration. 
It is noteworthy that the number of surviving myoblasts was significantly higher in the MB-
CSF-1 group compared to the MB group. Additional evidence for the long-term survival of 
myoblasts in the failing heart is that the LV infarction wall was thickest in the MB-CSF-1 
group; even significantly thicker than in the MB group. Moreover, the ejection fraction was 
improved  and  the  LV  dilation  ameliorated  significantly  in  the  MB-CSF-1  group.  Recent 
studies  indicate  that  there  is  a  lack  of  functional  electromechanical  coupling  between  the 
majority of grafted myoblasts and cardiomyocytes 
25, 26. This suggests that it is the enhanced 
number  of  grafted  myoblasts  and  the  increased  angiogenesis  induced  by  CSF-1  that 
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 contributes  to  the  improved  cardiac  function  we  have  observed  with  CSF-1-transfected 
myoblasts.  
The  capacity  of  myoblast  transplants  to  regenerate  myocardial  tissue  following  infarction 
depends on nourishment and spatially appropriate growth of myoblasts. This requires a potent 
neovasculature, appropriate MMP activity, and  proper fibrillar collagen scaffolding.  In the 
border zone, the number of vWF-positive vessels and expression of endothelial cell-specific 
CD31  was  increased  in  both  myoblast  transplant  groups.  However,  the  vascular  network 
formed  at  the  infarction  border  zone  was  highest  for  the  MB-CSF-1  group,  indicating  an 
additional  beneficial  angiogenic  effect  of  myoblast-derived  CSF-1.  Consistent  with  these 
angiogenic  effects,  CSF-1  stimulates  monocytes,  progenitors  of  macrophages,  to  secrete 
VEGF 
27 and in tumor settings CSF-1 through its action on macrophages has been shown to 
regulate angiogenesis 
14, 28. 
The  myocardial  MMP  profile  in  the  MB-CSF-1  group  suggests  that  CSF-1-induced 
recruitment of macrophages contributes to cardiac tissue remodeling and scar and collagen 
areas were smaller in the MB-CSF-1 group than in the other groups. In line with this, MMP-2 
and  macrophage  specific  MMP-12  were  overexpressed  in  the  border  zone  of  MB-CSF-1 
treated animals. Additionally, the expression of both MMP-9 and MMP-13 was reduced in the 
infarction zone in both myoblast groups 12 weeks post-infarction. Previous studies reported 
that MMPs were increased in post-infarction heart failure models, leading to LV dilation and 
that MMP-inhibitors beneficially affected cardiac remodeling and function 
29, 30. However, the 
excessive fibrosis without contractility or relaxation could accelerate cardiac remodeling and 
decrease cardiac function, as seen in ischemic or idiopathic dilated cardiomyopathy. In such 
cases, an increase in the MMP family and proteolysis of excess collagen may be a protective 
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 mechanism.  In  fact,  targeted  deletion  of  MMP-9  attenuated  LV  remodeling  and  collagen 
accumulation via overexpression of MMP-2 and MMP-13 
31. Furthermore, the importance of 
appropriate  expression  of  MMPs  has  been  demonstrated  in  mice  by  showing  that  acute 
myocardial infarction resulted in cardiac rupture in mice lacking MMP-3 or MMP-12, while 
lack of MMP-9 partially protected against rupture
32. 
Consistent  with  these  observations,  our  data  indicate  that  alteration  of  region-  and  type-
specific distribution of MMPs within the myocardium after infarction by CSF-1-producing 
myoblasts is associated with improved cardiac function. CSF-1 is likely to exert its effects on 
MMP-expression  via  enhanced  recruitment  of  macrophages  and  regulation  of  their  MMP 
production. This assumption is supported by previous findings in tumors in which CSF-1 was 
shown to enhance MMP expression and macrophage recruitment 
33. Moreover, macrophage 
recruitment may be related to increased absorption of necrotic tissues by phagocytosis. The 
failure of the recombinant CSF-1 group to beneficially affect remodeling and cardiac function 
compared  with  the  MB-CSF-1  group  may  be  due  to  prolonged  expression  of  CSF-1  by 
myoblasts, resulting in the maintenance of increased local CSF-1 concentrations for several 
weeks.  The  fact  that  MB-CSF-1  improved  cardiac  function,  resulting  in  CSF-1  over-
expression for at least 14 days, supports this hypothesis.   
 
Supplementary material 
Supplementary Materials and Methods are available online. 
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 Figure legends 
 
Figure 1. Functional analysis of hearts. Left ventricular ejection fraction (LVEF; A) and LV 
end-diastolic volume (LVEDV; B) within each group at different time points. Only CSF-1-
transfected myoblasts (MB-CSF-1) improved cardiac LVEF and LVEDV significantly over 
time, while LVEF and LVEDV of untreated myoblasts (MB), the recombinant human CSF-1 
(recCSF-1),  CSF-1  expression  plasmid  (pl-CSF-1),  and  untreated  control  groups  vs.  sham 
operated  rats  (Sham)  had  lesser  or  no  effects.  Data  are  expressed  as  means  ±SD.  *, 
significantly different from sham on days 7, 52, and 86, respectively; A: P<0.001; B: P<0.001 
for controls, MB, recCSF-1; P<0.001, P<0.001, and P=0.004 for pl-CSF-1, and P<0.001 and 
P=0.004  vs.  sham  group  on  days  7  and  52,  respectively,  for  MB-CSF-1.  †  significantly 
different within an individual group; A: P<0.001 and P=0.007, MB-CSF-1 vs. days 7 and 52, 
respectively; B: P<0.001, Control day 52 vs. day 7; P<0.001 and P=0.004, MB days 52 and 
86, respectively, vs. day 7; P<0.001, recCSF-1 day 52 vs. day 7; P<0.001, pl-CSF-1 day 52 
vs. day 7. ‡ significantly different from MB (A: P<0.001 for day 52, and P<0.001 for day 86 
vs. days 52, and 86; B: P=0.007 for day 52, and P<0.005 for day 86 vs. days 52 and d86. 
 
Figure  2.  Morphometric  analysis  of  hearts.  Representative  images  (A)  and  quantitative 
morphometric  analysis  (B)  of  collagenous  scar  tissue  in  left  ventricular  myocardium  by 
Goldner trichrome stain on day 88 after infarction in the control, MB, recCSF-1, pl-CSF-1, 
and MB-CSF-1  groups.  Left ventricular (LV) infarct wall thickness (C) and heart-to-body 
weight ratio (D). Data are expressed as means ±SD. *, significantly different from sham (C: 
P<0.001; D: P=0.002, P=0.012, P=0.003, and P=0.029 for controls, MB, recCSF-1, and pl-
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 CSF-1,  respectively);  †,  significantly  different  from  control,  MB,  recCSF-1,  and  pl-CSF-1 
(P<0.014).  
 
Figure  3.  Localization  of  DiIC18-labeled  autologous  rat  myoblasts  (DiI-MB)  and  DiIC18-
labeled  CSF-1-overexpressing  autologous  rat  myoblasts  (DiI  MB-CSF-1)  in  the  heart, 
obtained 88 days after infarction. (A) Representative white-light images (left), color-coded 
fluorescent map of DiIC18-signal (middle), and image overlays of the heart produced in Adobe 
Photoshop (right) showing the localization of DiIC18-labeled myoblasts (red/yellow) in the 
infarction area of the heart (Asterisk). The fluorescence signals from the implanted myoblasts 
in the heart are strongest in the DiI MB-CSF-1 group. LV, left ventricle; RV, right ventricle; 
the atriums are removed. (B) Representative red-channel fluorescence images of DiIC18-signal 
(left),  image  overlay  of  the  red  fluorescence  images  with  the  corresponding  section 
counterstained with DAPI (middle) and HE-staining of the same section (right) in the border 
zone of the DiI-MB and DiI MB-CSF-1 groups. The HE stain (right) defines the morphology 
in the border zone of the infarction area with integrated myoblasts. The myoblasts are easily 
identified on the fluorescent optical images from the surrounding tissue, because of their bright 
fluorescence. (C) Representative images of myocytes stained by skeletal muscle myosin heavy 
chain specific antibody in both the MB (upper image) and MB-CSF-1 (lower image) groups, 
showing integration of transplanted myoblasts (arrows) into neighboring myocardial tissue Bar 
= 50 µm. (D) Quantitative analysis of DiIC18-labeled grafted myoblasts in the heart. Data are 
expressed as means ±SD. *, significantly different from control and MB (P<0.02). (E) CSF-1 
gene transfer increases  proliferation of myoblasts in vitro. Values  are  expressed as means 
±SD. *, significantly different from MB (P=0.003) at 72 h. (F) PCNA stain (green) of DiIC18-
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 labeled (red) MB and MB-CSF-1 transplanted groups. PCNA-positive MBs are not detected. 
Occasional PCNA positive proliferative events of non-MB cells are detected (insert). 
 
Figure 4. Analysis of Angiogenesis. Representative vWF-stained sections in the MB (A, B) 
and  MB-CSF-1  (C,  D)  groups,  reveal  a  large  number  of  vessels  (arrows)  in  areas  with 
transplanted myoblasts. Bar = 50 µm. Quantification of vWF-positive vessels in myocardial 
tissue of the border zone (BZ) and the myocardial infarction zone (MI) 88 days after infarction 
per  high-power  field  (HPF;  E).  Representative  Western  blot  images  and  quantification  of 
protein levels of CD-31 Western blots in BZ and the MI zone 88 days after infarction. Actin 
was used as a loading control (LC) (F). Data are expressed as means ±SD. *, significantly 
different  vs.  sham  (E:  P<0.025;  F:  P<0.001);  †,  significantly  different  vs.  control  (E: 
P=0.001; F: P<0.001 for MB and MB-CSF-1, respectively, and P=0.01 for pl-CSF-1); ‡, 
significantly different from MB, recCSF-1, and pl-CSF-1 (P<0.001). 
 
Figure  5.  Analysis  of  CSF-1  expression  and  macrophages.  (A)  CSF-1  mRNA  expression 
levels  following  transfection  of  myoblasts  with  CSF-1  expression  plasmids  in  vitro, 
normalized  to  GAPDH.  *,  significantly  different  from  control  P<0.001).  (B)  Analysis  of 
myocardial  CSF-1  mRNA  expression  on  days  52  and  88  after  myocardial  infarction 
normalized to GAPDH. Data are expressed as means ±SD. *, significantly different from other 
groups (P<0.06). (C) Quantitative histo-morphometric analysis of myocardial tissue sections 
of the border zone on day 88 after infarction stained with the macrophage specific RM-4 
antibody.  Data  are  expressed  as  means  ±SD.  *,  significantly  different  from  control  (A: 
P<0.001;  B:  P=0.047).  Representative  immunocytochemistry  images  of  myocardial  tissue 
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 sections of the border zone on day 88 after infarction in MB (D, E) and MB-CSF-1 (F, G) 
group  stained  with  the  macrophage  specific  RM-4  antibody.  Arrowheads  indicate 
macrophages stained positively with RM-4 antibody inside the myocardial tissue. Calibration 
bar = 50 µm. 
 
Figure 6. Analysis of MMP Expression. (A) Quantification of protein expression levels of 
MMP-2, MMP-9, MMP-1, MMP-13, and MMP-12 and representative Western blot images in 
myocardial tissue of the border zone (BZ) and the myocardial infarction zone (MI) 88 days 
after myocardial infarction. Actin was used as a loading control (LC); SP, specific protein. 
Data are expressed as means ±SD. MMP-2: *, significantly different from control (P=0.006); 
MMP-9: *, significantly different from control (P<0.0001 for MB group; P=0.001 for MB-
CSF-1  group);  MMP-13:  *,  significantly  different  from  control  (P=0.045  for  MB  group; 
P=0.003 for MB-CSF-1 group); MMP-12: *, significantly different from control (P=0.039). 
(B)  Representative  immunocytochemistry  images  of  MMP-2-  (left  panels)  and  MMP-12- 
(right  panels)  stained  myocardial  sections  in  MB  (upper  panels)  and  MB-CSF-1  (lower 
panels). Both MMP-2- and MMP-12-positive cells (arrows) reveal a higher density in the MB-
CSF-1 group. Bar = 50 µm. 
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